US2014056887A1PendingUtilityA1

Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody

65
Assignee: BIOGEN IDEC INCPriority: Aug 11, 1998Filed: Nov 1, 2013Published: Feb 27, 2014
Est. expiryAug 11, 2018(expired)· nominal 20-yr term from priority
Inventors:Antonio J. Grillo-Lopez
A61P 35/04A61P 37/00A61P 35/00A61P 35/02A61P 43/00A61K 31/704C07K 16/2887A61K 31/475A61K 39/39541A61K 39/39558A61K 51/1027A61K 38/212A61K 2039/505A61K 31/675A61K 38/2013C07K 2317/24A61K 2039/545C07K 2317/77A61K 38/217A61K 31/573C02F 1/003C02F 2307/02C07K 2317/56A61K 51/1069A61K 38/193C07K 16/3061A61K 39/395
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of extending median time to progression for responders by at least 13 months in patients with relapsed or refractory, low grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma, comprising administering four doses of 375 mg/m 2  of rituximab to the patients. 
     
     
         2 . A method according to  claim 1 , wherein the patients exhibit an overall response rate to the administration of about 48%.

Join the waitlist — get patent alerts

Track US2014056887A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.